Preparing for the next pandemic is a global responsibility – the UK has a vital role to play
The Covid-19 pandemic was a powerful reminder that no country can stand alone in a global health crisis. It took unprecedented collaboration between governments, scientists, and industry to develop and deliver vaccines at speed. The UK played a leading role in this effort, from the rapid development of the Oxford-AstraZeneca vaccine to supporting global access through Covax – but now we risk being left behind.
The UK has long been a global leader in life sciences. Its research institutions, scientists, and companies are at the forefront of medical innovation. But developing a vaccine is only half the battle – ensuring it can be produced at scale and distributed quickly is just as crucial. The UK's leadership in science must be matched by manufacturing capacity and strength.
The Covid Inquiry has highlighted the need for onshore vaccine manufacturing to strengthen the UK's resilience in future pandemics. However, recent global developments raise concerns about long-term preparedness. If the UK is to maintain its position as a leader in global health, investment in vaccine manufacturing and stockpiling must remain a priority. In today's rapidly fragmenting world, it's a matter of self -reliance.
Many countries are learning from the lessons of Covid-19 and strengthening their vaccine security. The European Union, through its Health Emergency and Preparedness Authority (HERA), is investing in advanced manufacturing capabilities to ensure vaccine supply during health emergencies. Our sister company, Bilthoven Biologicals, is part of this initiative, contributing to a European-wide preparedness with a new facility which has just opened in the Netherlands.
We are continuing to grow and scale our efforts. At Serum Institute of India, we have built the world's largest pandemic preparedness facility, capable of producing between five and 10 billion doses in times of crisis, ensuring supply for India and beyond. We are also collaborating with organisations like CEPI for their 100 Days Mission, which aims to develop and deploy vaccines within 100 days of a new pandemic pathogen emerging.
These efforts reflect a broader recognition that pandemic preparedness requires sustained investment. And in this, public-private collaboration is key; governments and the private sector must work together to strengthen vaccine manufacturing and research.
Put simply: to ensure domestic manufacturing capacity remains strong and can rapidly scale up in a crisis, sustained government support is essential.
At the same time, global commitments to health security must remain strong. The UK is reportedly considering cuts to Gavi, the Vaccine Alliance, while the United States has withdrawn from the World Health Organization (WHO) and significantly reduced the workforce of the United States Agency for International Development (USAID) – a move that could weaken global pandemic preparedness efforts. These shifts risk undermining the very systems that helped combat Covid-19.
The pandemic taught us that no country can stand alone in a health crisis. It also reminded us how even the strongest supply chains and bilateral agreements can face unexpected challenges.
If we are to ensure global preparedness, governments must reinforce their commitments—not step away from them. This is why the UK must take steps to strengthen its capabilities and be ready to tackle any future health crisis.
More than reacting to crises, pandemic preparedness is about shaping the future. The UK has long been a pioneer in global health, and this is a moment to lead. The choice is clear: invest now and be ready – or risk being caught unprepared when the next pandemic strikes.
With the right investments, the UK can be sure that when the next global health emergency comes, vaccines reach all those who need them, quickly and equitably.
The window for action is now. By acting today, the UK can help create a world that never faces the same supply chain struggles, delays, and inequities that defined the last pandemic. The world will be watching – let's make sure history looks back on this moment as one where we got it right.
Adar Poonawalla is chief executive officer of the Serum Institute of India
Protect yourself and your family by learning more about Global Health Security
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNBC
37 minutes ago
- CNBC
Dollar poised for weekly loss, hurt by economic weakness and trade limbo
The dollar was headed for a weekly loss on Friday, undermined by signs of fragility in the U.S. economy and little progress on trade negotiations between Washington and its partners, ahead of a critical jobs report. The U.S. nonfarm payrolls report expected later on will draw greater scrutiny after a slew of weaker-than-expected economic data this week underscored that President Donald Trump's tariffs were taking a toll on the economy. Currencies were mostly rangebound in early European hours as traders steered clear of large bets ahead of the data release. The euro was taking a breather after hitting a 1-1/2-month top on Thursday following hawkish remarks from the European Central Bank. It last bought roughly $1.1422, down just 0.2% on the day. Traders have pushed back expectations on the timing of the next rate cut, but continue to anticipate a 25 basis point reduction by year-end. Deutsche Bank's Mark Wall said he still expects 50 basis points worth of ECB rate cuts, adding "it is still too early to judge the impact of trade war, and the path of the trade war is in any case still inherently unpredictable." Reflecting a struggling economy, data showed that German exports and industrial output fell more than expected in April and data on euro zone retail sales is expected later in the day. Sterling dipped 0.2% at around $1.3546 having scaled a more than three-year peak in the previous session, and was set to rise about 0.6% for the week. The yen fell 0.18% to 143.90 per dollar. Most currencies had surged against the dollar late on Thursday, helped by news that Trump and Chinese President Xi Jinping spoke on a call for more than an hour, before paring some of their gains. Against a basket of currencies, the dollar edged up to 98.9, and was headed for a weekly loss of 0.5%. Analysts said Friday's U.S. jobs data would likely be the next catalyst for currencies. Economists polled by Reuters forecast the U.S. economy created 130,000 new jobs in May versus 177,000 in April. Job growth likely slowed considerably in May as businesses struggled with headwinds from tariff uncertainty, but probably not enough for a cautious Federal Reserve to resume cutting interest rates anytime soon, analysts said. "Within all the noise... the softness that we've seen in the data this week has probably been more responsible for rejuvenating the bearish U.S. dollar narrative than anything else that's gone on," said Ray Attrill, head of FX research at National Australia Bank. "We've always taken the view that once it becomes clear that the U.S. economy is no longer exceptional, and that the policy actions that we've seen to date, together with the relative tightness of Fed policy, will start to show through particularly in a weakening labor market. Hence the importance of tonight's numbers." Adding to headwinds for the dollar, investors remain worried about U.S. trade negotiations and the lack of progress in hashing out deals ahead of an early July deadline. The highly anticipated call between Trump and Xi also provided little clarity and the spotlight on it was quickly stolen by a public fallout between Trump and Elon Musk.
Yahoo
39 minutes ago
- Yahoo
Best's Review Explores the Growth of the Residual Property Market
OLDWICK, N.J., June 06, 2025--(BUSINESS WIRE)--The June issue of Best's Review examines how the impact of climate risk and severe weather events has reshaped the insurance industry, even causing homeowners to turn to the so-called insurers of last resort, FAIR Plans: "The Last Resort: As Private Insurers Exit High-Risk Areas, FAIR Plans Find Competitive Foothold" reports how homeowners are turning to the residual market because of the decline in availability of coverage, even though FAIR Plan policies may cost more and offer less coverage. "Colorado FAIR Plan Launches With Help From Plans Countrywide, Director Says" explains the state's troubles and how its FAIR Plan aims to remedy them. "US Treasury's FIO: Home Insurance Affordability, Availability Undermined by Climate Risks" looks at a recent report from the U.S. Department of the Treasury's Federal Insurance Office and how industry groups are responding. "California Regulators Say Redrawn Wildfire Hazard Maps Will Protect Homes, Communities" explores how the California Department of Insurance wants to empower communities with more accurate information about the hazards faced by the state. Also included: "Large Language Models Examine Rising U.S. Homeowners Rates" presents responses from three artificial intelligence large language models about the forces driving the increase in homeowners rates. "Largest European Insurers – 2025 Edition" ranks non-IFRS 17 companies by 2023 gross premiums written and IFRS 17 companies by 2023 insurance service revenue. Best's Review is AM Best's monthly insurance magazine, covering emerging issues and trends and evaluating their impact on the marketplace. Access to the complete content of Best's Review is available here. For Best's Review advertising opportunities and a complete media kit, visit AM Best Advertising Services. AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit Copyright © 2025 by A.M. Best Company, Inc. and/or its affiliates. ALL RIGHTS RESERVED. View source version on Contacts Patricia Vowinkel Executive Editor, Best's Review +1 908 882 1771 Sign in to access your portfolio
Yahoo
43 minutes ago
- Yahoo
Discovering Europe's Undiscovered Gems In June 2025
As European markets navigate a landscape marked by easing inflation and potential ECB rate cuts, the pan-European STOXX Europe 600 Index has seen a modest rise, reflecting cautious optimism amid ongoing trade negotiations with the U.S. Against this backdrop of shifting economic indicators and market sentiment, identifying stocks that can thrive requires an eye for those companies poised to capitalize on these evolving conditions. Name Debt To Equity Revenue Growth Earnings Growth Health Rating AB Traction NA 5.39% 5.24% ★★★★★★ La Forestière Equatoriale NA -65.30% 37.55% ★★★★★★ Caisse Regionale de Credit Agricole Mutuel Toulouse 31 19.46% 0.47% 7.14% ★★★★★☆ Zespól Elektrocieplowni Wroclawskich KOGENERACJA 14.04% 21.73% 17.76% ★★★★★☆ Viohalco 93.48% 11.98% 14.19% ★★★★☆☆ Practic 5.21% 4.49% 7.23% ★★★★☆☆ Evergent Investments 5.39% 9.41% 21.17% ★★★★☆☆ Castellana Properties Socimi 53.49% 6.64% 21.96% ★★★★☆☆ Grenobloise d'Electronique et d'Automatismes Société Anonyme 0.01% 5.17% -13.11% ★★★★☆☆ MCH Group 124.09% 12.40% 43.58% ★★★★☆☆ Click here to see the full list of 326 stocks from our European Undiscovered Gems With Strong Fundamentals screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Value Rating: ★★★★★☆ Overview: Paul Hartmann AG is a company that produces and distributes medical and care products across various regions including Germany, the rest of Europe, the Middle East, Africa, Asia-Pacific, and the Americas with a market cap of €884.38 million. Operations: Paul Hartmann AG generates revenue primarily from its segments: Incontinence Management (€769.92 million), Wound Care (€608.93 million), Infection Management (€518.89 million), and Complementary Divisions (€510.18 million). Paul Hartmann, a notable player in the medical equipment sector, showcases impressive growth with earnings surging by 281.6% last year, outpacing the industry average of 14.1%. The company's price-to-earnings ratio stands attractively at 8.1x compared to the German market's 19.2x, suggesting potential undervaluation. Its interest payments are well-covered by EBIT at a robust 10.4 times coverage, indicating financial stability despite a net debt to equity ratio increase from 1.4% to 17.4% over five years—still within satisfactory limits underlining its solid footing in navigating fiscal challenges effectively. Click to explore a detailed breakdown of our findings in Paul Hartmann's health report. Examine Paul Hartmann's past performance report to understand how it has performed in the past. Simply Wall St Value Rating: ★★★★★★ Overview: TotalEnergies EP Gabon Société Anonyme is involved in the mining, exploration, and production of crude oil in Gabon with a market capitalization of €909 million. Operations: TotalEnergies EP Gabon generates revenue primarily from its oil and gas exploration and production activities, amounting to $464.72 million. The company's financial performance is significantly influenced by its ability to manage costs associated with these operations. TotalEnergies EP Gabon, a noteworthy player in the oil sector, has seen its earnings surge by 245.9% over the past year, outpacing the broader industry's -11.3%. The company is trading at a significant discount of 63.4% below estimated fair value, presenting an intriguing opportunity for investors. With a robust debt-to-equity ratio improvement from 1.7 to just 0.08 over five years and more cash than total debt, financial stability seems assured. Recent results show crude production slightly down at 16.7 kb/d for Q1 2025 compared to last year's same quarter but with net income climbing to $91 million from $26 million previously reported for full-year figures ending December 2024. Click here and access our complete health analysis report to understand the dynamics of TotalEnergies EP Gabon Société Anonyme. Explore historical data to track TotalEnergies EP Gabon Société Anonyme's performance over time in our Past section. Simply Wall St Value Rating: ★★★★★★ Overview: Ernst Russ AG is a publicly owned investment manager with a market cap of €227.07 million. Operations: Ernst Russ AG generates revenue primarily from its investment management activities. The company has a market cap of €227.07 million, reflecting its valuation in the financial markets. Ernst Russ AG, a small-cap entity in the shipping sector, has shown resilience despite challenges. Recent earnings for Q1 2025 revealed sales of €40.9 million compared to €46.9 million last year, but net income surged to €24.6 million from €13.8 million, reflecting improved profitability with basic EPS rising to €0.73 from €0.41. The company forecasts 2025 revenues between €147-167 million and EBIT from ship operations excluding vessel sales between €43-73 million, highlighting potential growth opportunities amidst operational adjustments and strategic asset disposals expected to generate significant capital gains this year. Dive into the specifics of Ernst Russ here with our thorough health report. Gain insights into Ernst Russ' historical performance by reviewing our past performance report. Access the full spectrum of 326 European Undiscovered Gems With Strong Fundamentals by clicking on this link. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include DB:PHH2 ENXTPA:EC and XTRA:HXCK. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio